Demencia vascular
Revisado por pares por Dr Colin Tidy, MRCGPÚltima actualización por Dr Hayley Willacy, FRCGP Last updated 25 Feb 2025
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Versión en audio
- Add to preferred sources on Google
Profesionales Médicos
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Pérdida de memoria y demencia article more useful, or one of our other artículos de salud.
En este artículo:
Synonym: vascular cognitive impairment
See the related separate articles Dementia, Apoyando a la familia de personas con demencia y Enfermedad de Alzheimer.
Continúa leyendo abajo
What is vascular dementia?
Vascular dementia (VaD) is not a single disease but a group of syndromes of cognitive impairment caused by different mechanisms causing ischaemia or haemorrhage secondary to cerebrovascular disease (multiple infarcts, single strategic infarct or small vessel disease.) Increasingly the term vascular cognitive impairment (VCI) is used to encompass the spectrum of deficit, in which VaD is the most severe form of the disease.1
Causes of vascular dementia (aetiology)
Volver al contenidoThe main subtypes of VaD are:
Stroke-related VaD. This incorporates multi-infarct dementia, the result of a series of small strokes, which in themselves may not be recognised, and single-infarct dementia, which occurs after a larger stroke.
Subcortical VaD (small-vessel disease or Binswanger's disease).2
Mixed dementia. Changes of both VaD and Alzheimer's disease are found together in the brain. The distinction between VaD and Alzheimer's dementia is becoming increasingly blurred because vascular risk factors play a role in both diseases and both types of dementia may co-exist in the same patient. 3 However, where they are seen mostly in white matter in VaD, in Alzheimer's dementia they predominate in cortical grey matter.
Most VaD is sporadic, but some cases display familial traits. Risk factors for VaD include:4
History of stroke or transient ischaemic attack (TIA).
Atrial fibrillation.
Hipertensión.
Diabetes mellitus.
Hyperlipidaemia.
Fumar.
Obesidad.
Enfermedad coronaria.
Family history of stroke or cardiovascular disease
Young-onset VaD has a genetic cause in some people.5
Continúa leyendo abajo
How common is vascular dementia? (Epidemiology)
Volver al contenidoVaD is the second most common form of dementia in the West after Alzheimer's disease. It is the most common form in some parts of Asia. Incidence increases with age.
VaD is thought to account for around 17% of dementia in the UK.
Prevalence of dementia following a first stroke varies depending on location and size of the infarct, definition of dementia, interval after stroke and age among other variables. Around one-third of individuals with stroke develop dementia within 5 years.6
Symptoms of vascular dementia (presentation)
Volver al contenidoCharacteristically, VaD is a progressive disease where deteriorations may be sudden or gradual but tend to progress in a stepwise manner. In contrast to acute confusional state (which is usually of recent onset and may have a reversible cause), in dementia the history should go back at least several months and usually several years.
NINDS-AIREN criteria for the clinical diagnosis of PROBABLE vascular dementia (VaD) - as recommended by the National Institute for Health and Care Excellence (NICE)5
Presence of dementia - cognitive decline from higher level of functioning. This can be demonstrated as memory loss plus impairment in two or more different cognitive domains (see 'Diagnosis', below). This should be established by clinical examination and neuropsychological testing. Deficits should be severe enough to interfere with activities of daily living - not secondary effects of the cerebrovascular event alone.
Cerebrovascular disease, defined by the presence of signs on neurological examination and/or by brain imaging.
A relationship between the above two disorders inferred by:
Onset of dementia within three months following a recognised stroke.
An abrupt deterioration in cognitive functions.
Fluctuating, stepwise progression of cognitive deficits.
Presentation varies significantly, as does speed of progression. Presenting features which may suggest a vascular cause include:
Focal neurological abnormalities: visual disturbances (eg, field defects), sensory or motor symptoms (eg, dysphasia, hemiparesis, visual field defects) or extrapyramidal signs (eg, dystonias and Parkinsonian features).
Difficulty with attention and concentration.
Convulsiones.
Depression and/or anxiety accompanying the memory disturbance.
Early presence of disturbance in gait, unsteadiness and frequent, unprovoked falls.
The patient has bladder symptoms (eg, incontinence) without a demonstrable urological condition.
Features of pseudobulbar palsy
Emotional problems - eg, emotional lability, psychomotor retardation or depression.
For objective evidence, carry out a test of cognitive functioning (see under 'Diagnosis', below).
Also consider dementia with Lewy bodies (DLB) in elderly patients presenting with hallucinations, lucid periods, movement disorders, falls or syncope. Making this diagnosis will have important implications for treatment, as the use of neuroleptics in these patients is associated with an increased risk of adverse reactions, and may cause an increase in mortality.5
Continúa leyendo abajo
Diagnosis of vascular dementia
Volver al contenidoVaD should not be diagnosed solely on the basis of a person having significant cardiovascular disease. The diagnosis of dementia requires:5
Historia clínica y examen físico exhaustivos. La clave para el diagnóstico es una buena historia de deterioro progresivo de la memoria y otras funciones cognitivas (generalmente requiriendo la ayuda de un cónyuge, familiar o amigo).
A formal screen for cognitive impairment - see the separate Screening for cognitive impairment article. Specific notes should be made on the following:
Memoria: tanto a corto como a largo plazo.
Individual cognitive domains:
Orientación - tiempo, lugar, persona.
Capacidad de atención y concentración.
Función del lenguaje (generalmente evidente durante el interrogatorio).
Visuospatial functions.
Executive function - problem solving, etc.
Motor control.
Práctica - si pueden vestirse, poner la mesa, etc.
Medication review to ensure cognitive decline is not due to medication.
Other reversible organic causes to have been excluded.
If the dementia subtype is uncertain and VaD is suspected, MRI is preferred. If MRI is unavailable or contra-indicated, use CT.5
MRI scanning may show evidence of infarcts, cortical lacunae, and extensive white matter changes.7 Appearances will vary depending on the pathogenesis. It may help distinguish VaD from Alzheimer's disease.
NB: it is important to identify depression and treat it appropriately. Sometimes it is difficult to distinguish between depression and dementia and depression is quite common in dementia. If in doubt, treat.
General management of vascular dementia
Volver al contenidoLike other dementias the treatment is symptomatic, addressing the individual's main problems and supporting the carers. Detecting and addressing cardiovascular risk factors is also very important to try to slow progression. See the separate Evaluación del riesgo cardiovascular article.
General principles of management of people with dementia are addressed in the separate Demencia article, and in National Institute for Health and Care Excellence (NICE) Quality Standards.8
Las intervenciones no farmacológicas deben adaptarse a las preferencias y capacidades de la persona, así como a los recursos locales, y ajustarse según la respuesta. Estas incluyen:
Programas de estimulación cognitiva.
Estimulación multisensorial.
Music and art therapy.
Baile.
Masaje.
Aromaterapia.
Programas de ejercicio estructurados.
Terapia asistida con animales.
Comorbid emotional or psychiatric disorders should be addressed by non-pharmacological means (as above) and pharmacological methods as appropriate.
Atención comunitaria y hospitalaria
Patients should be cared for in the community as much as possible. However, if they become severely disturbed and need to be contained for their own safety or the safety of others, inpatient care should be considered (this might include those liable to be detained under the Ley de Salud Mental de 1983). La admisión hospitalaria también estaría justificada para pacientes con problemas físicos y psiquiátricos complejos que no pudieran ser evaluados adecuadamente en la comunidad.
People with challenging behaviour5 8
This patient group is given a specific mention. They should be offered early assessment which includes:
Physical health.
Depression and any psychosocial issues.
Possible undetected pain or discomfort.
Adverse effects of medication.
Life history, including spiritual, cultural and religious identity.
Physical environment.
Behavioural and functional analysis by a skilled professional.
Factors which may exacerbate violent or aggressive behaviour, or increase the risk of harm to self or others, include:
Hacinamiento.
Falta de privacidad.
Aburrimiento o falta de actividad.
Comunicación deficiente.
Conflicto.
Liderazgo clínico débil en entornos de residencias de cuidado.
El personal debe identificar, monitorear y abordar factores como estos, y recibir capacitación en el manejo de la agresión o la agitación.
Pharmacological management of vascular dementia5
Volver al contenidoThere is no specific pharmacological treatment approved for the treatment of VaD. Only consider anticholinesterase (AChE) inhibitors or memantine for people with VaD if they have suspected comorbid Alzheimer's disease, Parkinson's disease dementia or dementia with Lewy bodies. A 2021 Cochrane review found moderate- to high-certainty evidence that donepezil 10 mg has the greatest effect on cognition, but at the cost of adverse effects.9 The effect is modest.
Cerebrolysin continues to be used and promoted as a treatment for VaD, but the supporting evidence base is weak.10
Medication for non-cognitive symptoms and challenging behaviour
This should only be used if there is severe distress or immediate risk of harm to the patient or others. NICE does not recommend the use of antipsychotics for mild-to-moderate non-cognitive symptoms in dementia with VaD or mixed dementia because of the increased risk of cerebrovascular adverse events and death.
For severe symptoms (eg, psychosis and/or agitated behaviour causing significant distress), antipsychotics should only be prescribed once the risks and benefits have fully been considered and discussed with carers, risk factors have been assessed and a regular assessment has been made of changes in cognition. Treatment, when considered appropriate, should be time-limited. Comorbid conditions such as depression should be considered and treated.
Urgent treatment of challenging behaviour
If intramuscular agents are required for behavioural control, NICE recommends lorazepam, haloperidol or olanzapine.5
If possible, a single agent should be used. If rapid tranquilisation is required, lorazepam and haloperidol should be used in combination. The patient should be monitored for dystonia and other extrapyramidal effects. Anticholinergic drugs may be used if side-effects become distressing, but monitor for deteriorating cognitive function.
Diazepam or chlorpromazine should be avoided.
Prevention of vascular dementia11
Volver al contenidoVaD is modifiable and preventable. Modifying vascular risk factors in mid-life may help to prevent stroke and VaD. The single most important modifiable risk factor in mid-life is hypertension, but the value of treating this is more debatable as age increases.1 There is not yet any convincing evidence that the treatment of hypertension reduces the incidence of dementia, although it appears likely that this is the case in mid-life treatment. There is evidence that lowering high blood pressure after stroke decreases the risk of post-stroke dementia.
Complications of vascular dementia12
Volver al contenidoBehavioural problems, including wandering, delusions, hallucinations and poor judgement.
Decubitus ulcers.
Caregiver burden and stress: this should be considered a complication of any dementia, including VaD. This can lead to increased psychiatric and medical morbidity in the caregiver.
Pronóstico
Volver al contenidoExclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.
Lecturas adicionales y referencias
- Bir SC, Khan MW, Javalkar V, et al; Emerging Concepts in Vascular Dementia: A Review. J Stroke Cerebrovasc Dis. 2021 Aug;30(8):105864. doi: 10.1016/j.jstrokecerebrovasdis.2021.105864. Epub 2021 May 29.
- Anand S, Schoo C; Mild Cognitive Impairment.
- Lee CS, Lee ML, Gibbons LE, et al; Associations Between Retinal Artery/Vein Occlusions and Risk of Vascular Dementia. J Alzheimers Dis. 2021;81(1):245-253. doi: 10.3233/JAD-201492.
- Gorelick PB, Scuteri A, Black SE, et al; Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.
- Vacaras V, Cordos AM, Rahovan I, et al; Binswanger's disease: Case presentation and differential diagnosis. Clin Case Rep. 2020 Oct 27;8(12):3450-3457. doi: 10.1002/ccr3.3459. eCollection 2020 Dec.
- Hurla M, Banaszek N, Kozubski W, et al; Enfermedad de Alzheimer y Demencia Vascular, Características que Conectan y Diferencian. Curr Alzheimer Res. 2024 Jul 29. doi: 10.2174/0115672050319219240711103459.
- Chang Wong E, Chang Chui H; Vascular Cognitive Impairment and Dementia. Continuum (Minneap Minn). 2022 Jun 1;28(3):750-780. doi: 10.1212/CON.0000000000001124.
- Demencia: evaluación, manejo y apoyo para personas que viven con demencia y sus cuidadores; Guía NICE (junio 2018)
- El Husseini N, Katzan IL, Rost NS, et al; Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2023 Jun;54(6):e272-e291. doi: 10.1161/STR.0000000000000430. Epub 2023 May 1.
- Demencia; NICE CKS, mayo de 2025 (solo acceso en Reino Unido)
- Demencia; Estándar de Calidad NICE, junio de 2019
- Battle CE, Abdul-Rahim AH, Shenkin SD, et al; Inhibidores de la colinesterasa para la demencia vascular y otros deterioros cognitivos vasculares: un metaanálisis en red. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306. doi: 10.1002/14651858.CD013306.pub2.
- Cui S, Chen N, Yang M, et al; Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019 Nov 11;2019(11). doi: 10.1002/14651858.CD008900.pub3.
- Reuben DB, Kremen S, Maust DT; Dementia Prevention and Treatment: A Narrative Review. JAMA Intern Med. 2024 May 1;184(5):563-572. doi: 10.1001/jamainternmed.2023.8522.
- Sanders AE, Schoo C, Kalish VB; Vascular Dementia.
Continúa leyendo abajo
About the authorView full bio

Dr Hayley Willacy, FRCGP
Médico General, Autor Médico
MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)
Dr Hayley Willacy was an NHS GP working in northwest England, who retired from clinical practice in 2022 after 30 years.
About the reviewerView full bio

Dr Colin Tidy, MRCGP
Médico General, Autor Médico
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy is an NHS Doctor, based in Oxfordshire.
Historial del artículo
La información en esta página está escrita y revisada por pares por clínicos calificados.
Next review due: 26 Feb 2028
25 Feb 2025 | Última versión

Pregunta, comparte, conecta.
Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.

¿Te sientes mal?
Evalúa tus síntomas en línea de forma gratuita